The multiplex bead array approach to identifying serum biomarkers associated with breast cancer

Breast Cancer Research

Volumn 11, Issue 2, 2009, Pages

  Kim, Byoung K ^a   Lee, Jong W ^b   Park, Pil J ^b   Shin, Yong S ^b   Lee, Won Y ^b   Lee, Kyung A ^b   Ye, Sena ^b   Hyun, Heesun ^b   Kang, Kyung N ^b   Yeo, Donghwa ^c   Kim, Youngdai ^c   Ohn, Sung Y ^d   Noh, Dong Y ^b   Kim, Chul W ^b  

^a The Armed Forces Capital Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

^d Hankuk Aviation University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALPHA 1 ANTITRYPIN; ALPHA 2 MACROGLOBULIN; ALPHA FETOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; BETA2 GLYCOPROTEIN 1; C REACTIVE PROTEIN; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CATHEPSIN B; CD40 LIGAND; CLUSTERIN; EPIDERMAL GROWTH FACTOR; FERRITIN; GALECTIN 3; GELSOLIN; HAPTOGLOBIN ALPHA; HEMOGLOBIN; HIGH MOLECULAR WEIGHT KININOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREALBUMIN; PROAPOLIPOPROTEIN A1; SERUM AMYLOID A; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VITAMIN D BINDING PROTEIN; VITRONECTIN;

ANTIBODY BEAD ARRAY; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PROTEIN MICROARRAY; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINE; ALGORITHM; BLOOD; BREAST TUMOR; CANCER STAGING; EARLY DIAGNOSIS; PROGNOSIS; PROTEOMICS;

ALGORITHMS; BREAST NEOPLASMS; EARLY DIAGNOSIS; FEMALE; HUMANS; NEOPLASM STAGING; PROGNOSIS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 67649538202     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2247     Document Type: Article

References (64)

1. Chu KC, Tarone RE, Kessler LG, Ries LA, Hankey BF, Miller BA, Edwards BK. Recent trends in US breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst 1996, 88:1571-1579. 10.1093/jnci/88.21.1571, 8901855.
2. Early Breast Cancer Trialists' Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. 10.1016/S0140-6736(05)66544-0, 15894097, Early Breast Cancer Trialists' Collaborative Group.
3. Schairer C, Mink PJ, Carroll L, Devesa SS. Probabilities of Death From Breast Cancer and Other Causes Among Female Breast Cancer Patients. J Natl Cancer Inst 2004, 96:1311-1321.
4. Antman K, Shea S. Screening mammography under age 50. JAMA 1999, 281:1470-1472. 10.1001/jama.281.16.1470, 10227298.
5. Bieglmayer C, Szepesi T, Kopp B, Hoffmann G, Petrik W, Guettuoche K, Grundler S, Gregorits M, Strasser M. CA 15.3, MCA, CAM 26, CAM 29 are members of a polymorphic family of mucin-like glycoproteins. Tumour Biol 1991, 12:138-148. 10.1159/000217699, 2068512.
6. Dnistrian AM, Schwartz MK, Greenberg EJ, Smith CA, Schwartz DC. Evaluation of CAM 26, CAM 29, CA 15.3 and CEA as circulating tumor markers in breast cancer patients. Tumour Biol 1991, 12:82-90. 10.1159/000217692, 2028182.
7. Gion M, Mione R, Leon AE, Luftner D, Molina R, Possinger K, Robertson JF. CA 27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur J Cancer 2001, 37:355-363. 10.1016/S0959-8049(00)00396-8, 11239757.
8. Molina R, Jo J, Filella X, Zanon G, Pahisa J, Munoz M, Farrus B, Latre ML, Escriche C, Estape J, Ballesta AM. c-erbB-2 oncoprotein, CEA and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat 1998, 51:109-119. 10.1023/A:1005734429304, 9879773.
9. Van Dalen A. Pre-operative tumor marker levels in patients with breast cancer and their prognosis. Tumour Biol 1990, 11:189-195. 10.1159/000217654, 2371496.
10. Van Dalen A. Significance of cytokeratin markers TPA, TPA (cyk), TPS and CYFRA 21.1 in metastatic disease. Anticancer Res 1996, 16:2345-2349.
11. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, Goike H, Lamerz R, Nap M, Sölétormos G, Stieber P. Tumor Markers in Breast Cancer - European Group on Tumor Markers Recommendations. Tumour Biol 2005, 26:281-293. 10.1159/000089260, 16254457.
12. Chan DW, Beveridge RA, Muss H, Fritsche HA, Hortobagyi G, Theriault R, Kiang D, Kennedy BJ, Evelegh M. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol 1997, 15:2322-2328.
13. Karas M, Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal Chem 1988, 60:2299-2301. 10.1021/ac00171a028, 3239801.
14. Hutchens TW, Yip TT. New desorption strategies for the mass spectrometric analysis of micromolecules. Rapid Commun Mass Spectrom 1993, 7:576-580. 10.1002/rcm.1290070703.
15. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002, 48:1296-1304.
16. Borrebaeck CAK. Antibody microarray-based oncoproteomics. Expert Opin Biol Ther 2006, 6:833-838. 10.1517/14712598.6.8.833, 16856804.
17. Knezevic V, Leethanakul C, Bichsel VE, Worth JM, Prabhu VV, Gutkind JS, Liotta LA, Munson PJ, Petricoin EF, Krizman DB. Proteomic profiling of the cancer microenvironment by antibody arrays. Proteomics 2001, 1:1271-1278. 10.1002/1615-9861(200110)1:10<1271::AID-PROT1271>3.0.CO;2-6, 11721638.
18. Miller JC, Zhou H, Kwekel J, Cavallo R, Burke J, Butler EB, Teh BS, Haab BB. Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 2003, 3:56-63. 10.1002/pmic.200390009, 12548634.
19. Jain KK. Personalised medicine for cancer: from drug development into clinical practice. Expert Opin Pharmacother 2005, 6:1463-1476. 10.1517/14656566.6.9.1463, 16086635.
20. Louhimo J, Finne P, Alfthan H, Stenman UH, Haglund C. Combination of HCGbeta, CA 19-9 and CEA with logistic regression improves accuracy in gastrointestinal malignancies. Anticancer Res 2002, 22:1759-1764.
21. Carlsson A, Wingren C, Ingvarsson J, Ellmark P, Baldertorp B, Fernö M, Olsson H, Borrebaeck CA. Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays. Eur J Cancer 2008, 44:472-480. 10.1016/j.ejca.2007.11.025, 18171612.
22. Nolen BM, Marks JR, Ta'san S, Rand A, Luong TM, Wang Y, Blackwell K, Lokshin A. Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Res 2008, 10:R45. 2481492, 18474099, 10.1186/bcr2096.
23. Westgard JO, Barry PL, Hunt MR, Groth T. A multi-rule Shewhart chart for quality control in clinical chemistry. Clin Chem 1981, 27:493-501.
24. The R project of statistical computing. , http://www.r-project.org
25. Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, Thun MJ. Global Cancer Facts & Figures 2007. 2007, Atlanta, GA: American Cancer Society.
26. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006, 56:106-130. 10.3322/canjclin.56.2.106, 16514137.
27. Levenson VV. Biomarkers for early detection of breast cancer: what, when, and where?. Biochim Biophys Acta 2007, 1770:847-856.
28. Vazquez-martin A, Colomer R, Menendeza JA. Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer. Eur J Cancer 2007, 43:1117-1124. 10.1016/j.ejca.2007.01.037, 17379503.
29. Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpé S, Vermeulen PB, Dirix LY. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 2004, 10:7157-7162. 10.1158/1078-0432.CCR-04-0812, 15534087.
30. Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l'Hotel-dieu de Paris 1865, 3:654-712. London: New Sydenham Society.
31. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007, 110:1723-1729. 1976377, 17496204, 10.1182/blood-2006-10-053736.
32. Roselli M, Mineo TC, Basili S, Martini F, Mariotti S, Aloe S, Del Monte G, Ambrogi V, Spila A, Palmirotta R, D'Alessandro R, Davì G, Guadagni F, Ferroni P. Soluble CD40 ligand plasma levels in lung cancer. Clin Cancer Res 2004, 10:610-614. 10.1158/1078-0432.CCR-0348-03, 14760083.
33. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001, 58:4-43. 10.1007/PL00000776, 11229815.
34. Amirkhosravi A, Amaya M, Desai H, Francis JL. Platelet-CD40 ligand interaction with melanoma cell and monocyte CD40 enhances cellular procoagulant activity. Blood Coagul Fibrinolysis 2002, 13:505-512. 10.1097/00001721-200209000-00005, 12192302.
35. Lerner WA, Pearlstein E, Ambrogio C, Karpatkin S. A new mechanism for tumor-induced platelet aggregation, comparison with mechanisms shared by other tumors with possible pharmacologic strategy toward prevention of metastases. Int J Cancer 1983, 31:463-469. 10.1002/ijc.2910310411, 6299977.
36. Gabrijelcic D, Svetic B, Spaiæ D, Skrk J, Budihna J, Turk V. Determination of cathepsins B, H, L and kininogen in breast cancer patients. Agents Actions Suppl 1992, 38:350-357.
37. Song JS, Sainz IM, Cosenza SC, Isordia-Salas I, Bior A, Bradford HN, Guo YL, Pixley RA, Reddy EP, Colman RW. Inhibition of tumor angiogenesis in vivo by a monoclonal antibody targeted to domain 5 of high molecular weight kininogen. Blood 2004, 104:2065-2072. 10.1182/blood-2004-02-0449, 15161672.
38. Foekens JA, Schmitt M, van Putten WL, Peters HA, Kramer MD, Jänicke F, Klijn JG. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 1994, 12:1648-1658.
39. Loskutoff DJ, Curriden SA, Hu G, Deng G. Regulation of cell adhesion by PAI. APMIS 1999, 107:54-61.
40. Bajou K, Noël A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998, 4:923-928. 10.1038/nm0898-923, 9701244.
41. Webb DJ, Thomas KS, Gonias SL. Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signalling and thereby promotes MCF-7 cell growth. J Cell Biol 2001, 152:741-752. 2195772, 11266465, 10.1083/jcb.152.4.741.
42. Declerck PJ, De Mol M, Vaughan DE, Collen D. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator. J Biol Chem 1992, 267:11693-11696.
43. Brogren H, Sihlbom C, Wallmark K, Lönn M, Deinum J, Karlsson L, Jern S. Heterogeneous glycosylation patterns of human PAI-1 may reveal its cellular origin. Thromb Res 2008, 122:271-278. 10.1016/j.thromres.2008.04.008, 18508114.
44. Di Micco P, Romano M, Niglio A, Nozzolillo P, Federico A, Petronella P, Nunziata L, Di Micco B, Torella R. Alteration of haemostasis in non-metastatic gastric cancer. Dig Liver Dis 2001, 33:546-550. 10.1016/S1590-8658(01)80105-5, 11816542.
45. Blackwell K, Haroon Z, Broadwater G, Berry D, Harris L, Iglehart JD, Dewhirst M, Greenberg C. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol 2000, 18:600-608.
46. Ferrigno D, Buccheri G, Ricca I. Prognostic significance of blood coagulation tests in lung cancer. Eur Respir J 2001, 17:667-673. 10.1183/09031936.01.17406670, 11401062.
47. Gearing AJ, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993, 14:506-512. 10.1016/0167-5699(93)90267-O, 7506035.
48. Koch AE, Halloran MM, Haskell CJ, Shah MR, Polverini PF. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 1995, 376:517-519. 10.1038/376517a0, 7543654.
49. Silva HC, Garcao F, Coutinho EC, De Oliveira CF, Regateiro FJ. Soluble VCAM-1 and E-selectin in breast cancer: relationship with staging and with the detection of circulating cancer cells. Neoplasma 2006, 53:538-543.
50. Bonello N, Norman RJ. Soluble adhesion molecules in serum throughout the menstrual cycle. Hum Reprod 2002, 17:2272-2278. 10.1093/humrep/17.9.2272, 12202413.
51. Hapke S, Kessler H, Luber B, Benge A, Hutzler P, Höfler H, Schmitt M, Reuning U. Ovarian cancer cell proliferation and motility is induced by engagement of integrin alpha(v)beta3/Vitronectin interaction. Biol Chem 2003, 384:1073-1083. 10.1515/BC.2003.120, 12956424.
52. Carriero MV, Del Vecchio S, Capozzoli M, Franco P, Fontana L, Zannetti A, Botti G, D'Aiuto G, Salvatore M, Stoppelli MP. Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res 1999, 59:5307-5314.
53. Madsen CD, Ferraris GM, Andolfo A, Cunningham O, Sidenius N. uPAR-induced cell adhesion and migration: vitronectin provides the key. J Cell Biol 2007, 177:927-939. 2064291, 17548516, 10.1083/jcb.200612058.
54. Zhou A, Huntington JA, Pannu NS, Carrell RW, Read RJ. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol 2003, 10:541-544. 10.1038/nsb943, 12808446.
55. Kenny HA, Kaur S, Coussens LM, Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest 2008, 118:1367-1379. 2267016, 18340378, 10.1172/JCI33775.
56. Paradis V, Degos F, Dargère D, Pham N, Belghiti J, Degott C, Janeau JL, Bezeaud A, Delforge D, Cubizolles M, Laurendeau I, Bedossa P. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 2005, 41:40-47. 10.1002/hep.20505, 15690480.
57. Hellman K, Alaiya AA, Schedvins K, Steinberg W, Hellström AC, Auer G. Protein expression patterns in primary carcinoma of the vagina. Br J Cancer 2004, 91:319-326.
58. Moore LE, Fung ET, McGuire M, Rabkin CC, Molinaro A, Wang Z, Zhang F, Wang J, Yip C, Meng XY, Pfeiffer RM. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomarkers Prev 2006, 15:1641-1646. 10.1158/1055-9965.EPI-05-0980, 16985025.
59. Chahed K, Kabbage M, Ehret-Sabatier L, Lemaitre-Guillier C, Remadi S, Hoebeke J, Chouchane L. Expression of fibrinogen E-fragment and fibrin E-fragment is inhibited in the human infiltrating ductal carcinoma of the breast: the two-dimensional electrophoresis and MALDI-TOF-mass spectrometry analyses. Int J Oncol 2005, 27:1425-1431.
60. Zannis VI, Chroni A, Krieger M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med 2006, 84:276-294. 10.1007/s00109-005-0030-4, 16501936.
61. Shah FD, Shukla SN, Shah PM, Patel HR, Patel P. Significance of alterations in plasma lipid profile levels in breast cancer. Integr Cancer Ther 2008, 7:33-41. 10.1177/1534735407313883, 18292593.
62. Furberg AS, Jasienska G, Bjurstam N, Torjesen PA, Emaus A, Lipson SF, Ellison PT, Thune I. Metabolic and hormonal profiles: HDL cholesterol as a plausible biomarker of breast cancer risk. The Norwegian EBBA Study. Cancer Epidemiol Biomarkers Prev 2005, 14:33-40.
63. Haddad JG. Plasma vitamin D-binding protein (Gc-globulin): multiple tasks. J Steroid Biochem Mol Biol 1995, 53:579-582. 10.1016/0960-0760(95)00104-8, 7626513.
64. Yamamoto N, Naraparaju VR, Asbell SO. Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients. Cancer Res 1996, 56:2827-2831.